For a Safer Outcome with Newborn Jaundice

Indian Pediatrics

Volumn 41, Issue 4, 2004, Pages 321-326

  Bhutani, Vinod K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; PHENOBARBITAL;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMORBIDITY; EDITORIAL; FOLLOW UP; GESTATIONAL AGE; HEALTH CARE POLICY; HUMAN; HYPERBILIRUBINEMIA; INTELLIGENCE QUOTIENT; KERNICTERUS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEWBORN JAUNDICE; RISK ASSESSMENT; UNITED STATES;

BILIRUBIN; HUMANS; INFANT, NEWBORN; JAUNDICE, NEONATAL; KERNICTERUS;

EID: 1942469587     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of Kernicterus. J Pediatr 2002;140:396-403.
2. JCAHO Sentinel Event Alert: Kernicterus Threatens Healthy Babies. www.JACHO.org. Issue 18, April 2001.
3. Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities. Kernicterus Prevention and Research. http://www.cdc.gov/ncbddd/dd/kernres.htm
4. American Academy of Pediatrics Practice Parameter: Management of hyperbilirubinemia in the healthy term newborns. Pediatrics 1994;94:558-565.
5. Bhutani VK, Johnson LH. Newborn jaundice and kernicterushealth and societal perspectives. Indian J Pediatr 2003;70:407-416
6. Johnson L, Bhutani VK. Guidelines for management of the jaundiced term and near-term infant. Clin Perinatol. 1998;25:555-574.
7. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992;89:809-818. and accompanied comments: 819-831.
8. Watchko JF, Oski FA. Bilirubin 20 mg/dL = vigintiphobia. Pediatrics. 1983;71:660-663.
9. Newman TB, Maisels MJ. Does hyperbilirubinernia damage the brain of healthy full-term infants? Clin Perinatol 1990;17:331-358.
10. Bhutani VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR, MD, Yeargin-Allsopp M, Kernicterus: Epidemiological Strategies for its Prevention through Systems-Based Approaches. J Perinatol 2004;24(8) (in press).
11. Serious reportable events report. A Consensus Report: A National Framework for Healthcare Quality Measurement and Reporting: National Quality Forum http://www.qualityforum.org/activities/ca_archive.htm
12. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999;104:6-14.
13. Ip S, Glicken S, Kulig J, O'Brien R, Sege R. Management of Neonatal Hyperbilirubinernia. Summary, Evidence Report/Technology Assessment: Number 65. AHRQ Publication No.03 E005, March 2002. Agency for Healthcare Research and Quality, Rockville, MD.
14. AAP Subcommittee on Neonatal hyperbilirubinemia. Neonatal Jaundice and kemicterus. Pediatrics. 2001;108:763-765.
15. Dennery, PA, Seidman, D, Stevenson, DK. Neonatal Hyperbilirubinemia. N Engl J Med 2001;334:581.
16. Arya VB, Agarwal R, Paul VK and Deorari, AK. Efficacy of Oral Phenobarbitone in Term "At Risk" Neonates in Decreasing Neonatal Hyperbilirubinemia: A Randomized Double-blinded, Placebo Controlled Trial. Indian Pediatr 2004;41:327-332.
17. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics 2004;113:119-123.
18. Alexander D. A method for interdicting the dovelopment of severe jaundice in development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics 2004;113:135.
19. Kreamer BL, Siegel FL, Gourley GR. A novel inhibitor of beta-glucuronidase: L-aspartic acid. Pediatr Res 2001;50:460-466.
20. Institute of Medicine (IOM): To Err is Human: Building a Safer Health System. Eds. Kohn LA, Corrigan JM, Donaldson MS. (Committee on Quality of Health Care in America). National Academy Press Washington, D.C. 1999.